Tempus AI, Inc. (TEM) rises after a new Recursion Pharmaceuticals partnership extension and RNA model agreement fueled renewed interest in its healthcare AI platform. Strong volume, recent FDA clearance, and ARPA-H funding added to the rally, though the stock now trades above several analyst targets.
Tempus AI, Inc. (TEM) rises 7.4% on Sept. 24 as investors react to a fresh Recursion Pharmaceuticals partnership extension, a new RNA foundation model agreement, and continued healthcare AI momentum. The move also reflects strong volume and recent regulatory and funding wins, but the stock now trades above several analyst targets, which raises the risk of chasing the rally.
Tempus AI, Inc. (TEM) rises 7.38% to $82.24 at the 4:00 p.m. ET regular-session print on Sept. 24, 2026. Relative volume reached 1.6x the 200-day average, giving the gain more weight than a thinly traded pop.
The strongest catalyst is continuation buying after Tempus extended its Recursion Pharmaceuticals data partnership and added a new RNA foundation model agreement on Sept. 21. Recent healthcare AI news, analyst activity, and strong sentiment have combined to keep TEM in focus.
Key Takeaways
TEM gained 7.38% to $82.24, with relative volume at 1.6x its 200-day average.
The clearest catalyst is the Sept. 21 Recursion agreement extension through November 2029 and new RNA model license.
Tempus has beaten quarterly EPS estimates in 6 of its last 7 reported quarters, but the company still reports negative EPS.
The share price sits above the $69.90 consensus target and the $80 high target, raising the risk of chasing momentum.
What's Driving Tempus AI's Rally Today
The newest named company event is Tempus' Sept. 21 announcement with Recursion Pharmaceuticals. The companies extended their multi-year data partnership through November 2029. They also entered a new agreement covering Recursion's RNA foundation model.
That agreement strengthens Tempus' position as a data and AI infrastructure provider. It also gives investors a concrete example of an outside biotech using Tempus' clinical and molecular data capabilities. In a market that often rewards an attractive narrative before it rewards profits, a named commercial renewal carries useful credibility.
Two other developments support the move. On Sept. 9, Tempus secured up to $9.5 million in ARPA-H ADVOCATE funding to deploy an autonomous AI system in cardiology. Earlier, on Aug. 24, the FDA granted 510(k) clearance for Tempus ECG-PH, software that analyzes standard 12-lead ECGs for signs linked to pulmonary hypertension.
Together, these events broaden the story beyond oncology. They connect Tempus to drug discovery, cardiology, regulated medical software, and precision medicine. The 1.6x volume reading fits a market repricing a platform story, rather than a random one-day spike.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Why Tempus AI's Data Platform Matters to Investors
Tempus operates a healthcare technology platform that links clinical workflows with laboratory diagnostics, analytics, and a repository of multimodal data. Its Hub application supports physicians using next-generation sequencing tests. This structure gives the company several ways to monetize one data foundation.
The Recursion transaction is important because it reinforces external demand for that foundation. A partnership extension through 2029 provides a longer commercial relationship. The additional RNA model license also places Tempus closer to the artificial intelligence infrastructure layer in drug development.
Meanwhile, the ARPA-H award and ECG-PH clearance show a second path. Tempus can apply its data and software capabilities to regulated clinical tools. That combination gives the company a broader competitive position than a single diagnostic test provider.
Still, breadth alone does not guarantee shareholder returns. The market must eventually connect partnerships, products, and clinical adoption to stronger earnings. For now, the recent news gives investors a clearer reason to value Tempus as a healthcare AI platform.
Tempus AI Financials and Valuation After the Move
Tempus remains a growth company with a profitability gap. The latest quarterly earnings history shows EPS of -$0.35 against an estimate of -$0.41 on July 30, a 14.6% upside surprise. The company has beaten EPS estimates in 6 of its last 7 reported quarters.
However, the broader stock data lists EPS at -$1.43. That figure keeps earnings risk central to the investment case. With a $14.41B market capitalization, TEM trades on expected platform expansion rather than established bottom-line profits.
A conventional price-to-earnings framework offers limited help while EPS remains negative. Therefore, investors must place more weight on commercial partnerships, product approvals, and the company’s record of quarterly execution. The recent beat history helps, but it does not remove the valuation burden.
The price also deserves attention. TEM closed at $82.24, above the analyst consensus target of $69.90 and the listed high target of $80. Goldman Sachs initiated coverage with a Neutral rating and a $75 target on Sept. 21. UBS also initiated coverage with a Neutral rating and a $70 target on Sept. 9.
TEM Analyst Outlook and Actionable Investor Insight
Analyst opinion remains constructive but mixed. The consensus includes 9 Buy ratings and 5 Hold ratings, with no Sell ratings. Cantor Fitzgerald initiated TEM at Overweight with an $80 target, while Piper Sandler upgraded the stock to Overweight and set a $76 target.
That backdrop supports the bullish platform narrative, yet the share price has moved beyond several published targets. The difference matters. Positive news can lift a stock quickly, but a price above consensus targets leaves less room for execution errors.
For existing holders, the Recursion extension, ARPA-H award, and FDA clearance support the thesis that Tempus is expanding beyond a narrow diagnostics business. For new capital, the disciplined approach is to separate momentum from value. The 7.38% gain and above-average volume confirm strong demand today, while negative EPS and a 3.724 beta point to meaningful risk.
TEM also remains below its 52-week high of $104.32, despite trading well above its $40.77 low. That range shows how quickly sentiment can change. Investors who enter after a sharp rise should size positions around volatility rather than treat positive sentiment as a substitute for earnings progress.
What Tempus AI's Rally Means for Investors
TEM rises on a credible cluster of developments, led by the Recursion data partnership extension and new RNA foundation model license. The strong volume confirms that traders are treating those events as evidence of a broader healthcare AI platform.
The opportunity is real, but so is the premium. Tempus has improving quarterly EPS execution and powerful strategic positioning, yet negative earnings and a price above most analyst targets make discipline essential after this move.
TEM is rising because investors are reacting to Tempus' extended partnership with Recursion Pharmaceuticals and a new RNA foundation model agreement. Strong volume, recent FDA clearance, and ARPA-H funding are also reinforcing the bullish move.
+Should I buy TEM stock now?
The article supports a cautious approach rather than an aggressive chase. TEM has strong momentum and credible catalysts, but it is already trading above several analyst targets and still carries negative earnings risk.
+What is the main catalyst behind Tempus AI's rally?
The main catalyst is the Sept. 21 Recursion Pharmaceuticals announcement, which extended the data partnership through November 2029 and added a new RNA foundation model license. That deal strengthens Tempus' case as a healthcare AI platform.
+Is Tempus AI profitable yet?
No, Tempus AI is still reporting negative EPS, so profitability remains a key risk. The company has beaten earnings estimates often, but investors are still valuing it mainly on growth, partnerships, and platform expansion.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on TEM?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
